IRIS
GANDAGLIA, GIORGIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 9.773
AS - Asia 8.360
NA - Nord America 4.891
SA - Sud America 2.576
AF - Africa 199
OC - Oceania 13
Continente sconosciuto - Info sul continente non disponibili 4
AN - Antartide 1
Totale 25.817
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 5.201
US - Stati Uniti d'America 4.649
SG - Singapore 3.083
CN - Cina 2.205
BR - Brasile 2.113
IT - Italia 1.877
HK - Hong Kong 1.256
SE - Svezia 1.033
VN - Vietnam 916
FR - Francia 481
DE - Germania 276
AR - Argentina 214
GB - Regno Unito 172
NL - Olanda 164
IN - India 158
FI - Finlandia 152
JP - Giappone 136
BD - Bangladesh 106
CA - Canada 104
TR - Turchia 89
IQ - Iraq 79
MX - Messico 76
IE - Irlanda 71
PL - Polonia 66
ZA - Sudafrica 66
CO - Colombia 65
EC - Ecuador 65
ID - Indonesia 63
AT - Austria 62
ES - Italia 51
MA - Marocco 46
PK - Pakistan 39
SA - Arabia Saudita 35
VE - Venezuela 30
UA - Ucraina 29
PY - Paraguay 27
CL - Cile 23
UZ - Uzbekistan 23
LT - Lituania 22
PH - Filippine 21
PE - Perù 18
TN - Tunisia 18
EG - Egitto 17
AE - Emirati Arabi Uniti 16
DO - Repubblica Dominicana 16
KE - Kenya 16
CZ - Repubblica Ceca 14
NP - Nepal 14
JO - Giordania 12
UY - Uruguay 12
BE - Belgio 11
CH - Svizzera 11
DZ - Algeria 11
IL - Israele 11
BG - Bulgaria 10
KZ - Kazakistan 10
MY - Malesia 10
PT - Portogallo 10
AU - Australia 9
AZ - Azerbaigian 9
LB - Libano 8
BA - Bosnia-Erzegovina 7
BO - Bolivia 7
HN - Honduras 7
IR - Iran 7
KR - Corea 7
NO - Norvegia 7
CR - Costa Rica 6
DK - Danimarca 6
ET - Etiopia 6
HU - Ungheria 6
PA - Panama 6
AL - Albania 5
BH - Bahrain 5
GT - Guatemala 5
OM - Oman 5
RO - Romania 5
AM - Armenia 4
BB - Barbados 4
CG - Congo 4
GR - Grecia 4
JM - Giamaica 4
SN - Senegal 4
SY - Repubblica araba siriana 4
TH - Thailandia 4
TT - Trinidad e Tobago 4
BW - Botswana 3
BY - Bielorussia 3
CY - Cipro 3
KG - Kirghizistan 3
KH - Cambogia 3
KW - Kuwait 3
MD - Moldavia 3
MK - Macedonia 3
NZ - Nuova Zelanda 3
PR - Porto Rico 3
PS - Palestinian Territory 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
SV - El Salvador 3
Totale 25.782
Salva come PNG Salva come JPEG
Città #
Singapore 1.269
Hong Kong 1.245
Moscow 1.211
Dallas 771
Ashburn 661
San Jose 582
Shanghai 471
Hefei 440
Lawrence 412
Princeton 408
Milan 404
Lauterbourg 385
Ho Chi Minh City 330
Beijing 227
Hanoi 204
New York 201
São Paulo 164
Rome 136
Los Angeles 129
Helsinki 106
Rio de Janeiro 71
Dublin 70
Nuremberg 64
Munich 63
Santa Clara 60
Turin 56
Warsaw 53
Orem 52
Tokyo 50
Boardman 49
Belo Horizonte 44
Da Nang 42
Montreal 41
Brooklyn 40
Chennai 37
Bologna 36
Brasília 36
Verona 36
Florence 35
Curitiba 34
Guangzhou 34
Haiphong 34
Porto Alegre 34
Chicago 32
Turku 31
Johannesburg 29
Baghdad 28
Vienna 28
Atlanta 27
Biên Hòa 27
Denver 27
Manchester 27
Genoa 26
London 26
Stockholm 26
Palermo 25
Salvador 25
Ankara 24
Frankfurt am Main 24
Phoenix 24
Buenos Aires 23
Council Bluffs 23
The Dalles 23
Amsterdam 22
Brescia 22
Guayaquil 22
Houston 22
Naples 22
Manaus 21
Toronto 21
Fortaleza 20
Mexico City 20
Pune 20
Seattle 20
Tashkent 20
Thái Bình 20
Bari 19
Boston 19
Campinas 19
Columbus 19
Goiânia 19
Poplar 19
Erbil 18
Paris 18
Dhaka 17
Ninh Bình 17
San Francisco 17
Betim 16
Hangzhou 16
Tianjin 16
Washington 16
Caxias do Sul 15
Hải Dương 15
Jeddah 15
Mumbai 15
New Delhi 15
Quito 15
Sumaré 15
Barnet 14
Borås 14
Totale 12.022
Salva come PNG Salva come JPEG
Nome #
External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection 1.825
[18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab 205
Impact of prostate imaging quality (PI-QUAL) score on the detection of clinically significant prostate cancer at biopsy 171
A NOVEL MODEL INTEGRATING CLINICAL, MP-MRI, AND EPIGENOMIC FEATURES TO PREDICT LYMPH NODE INVASION IN PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY AND PELVIC LYMPH NODE DISSECTION 155
[C-11]Choline PET/CT predicts survival in hormone-naive prostate cancer patients with biochemical failure after radical prostatectomy 154
How to optimize follow-up in patients with a suspicious multiparametric MRI and a subsequent negative targeted prostate biopsy. Results from a large, single-institution series 139
Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard 134
68Ga-PSMA-PET/CT Scan as Primary Staging for Prostate Cancer and Its Related Clinical Implications 131
ROBOT-ASSISTED RADICAL PROSTATECTOMY IS ASSOCIATED WITH FASTER AND GREATER RECOVERY FROM ORGASM ASSOCIATED INCONTINENCE 127
A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies 126
Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer 126
[Management of erectile dysfunction in patients with preexisting cardiovascular disease]. FT Disfunzione erettile nel paziente cardiopatico: diagnosi e raccomandazioni terapeutiche. 123
Age and gleason score upgrading between prostate biopsy and radical prostatectomy: Is this still true in the multiparametric resonance imaging era? 121
Identification of the Optimal Candidates for Nodal Staging with Extended Pelvic Lymph Node Dissection Among Prostate Cancer Patients Who Underwent Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography. External Validation of the Memorial Sloan Kettering Cancer Center and Briganti Nomograms and Development of a Novel Tool 120
Positive Predictive Value of Prostate Imaging Reporting and Data System Version 2 for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis 119
A MINIMUM OF 14 CORES SHOULD BE TAKEN AT BIOPSY BEFORE PLANNING ACTIVE SURVEILLANCE FOR PATIENTS WITH LOW-RISK PROSTATE CANCER 117
Prostate-specific membrane antigen Radioguided Surgery to Detect Nodal Metastases in Primary Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Results of a Planned Interim Analysis of a Prospective Phase 2 Study 116
Impact of prostate MRI central review over the diagnostic performance of MRI-targeted biopsy: should we routinely ask for an expert second opinion? 111
A population-based competing-risks analysis of survival after nephrectomy for renal cell carcinoma 111
Variability of mpMRI diagnostic performance according to the upfront individual patient risk of having clinically significant prostate cancer 110
Which Patients with Prostate Cancer and Lymph Node Uptake at Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography/Computerized Tomography Scan Are at a Higher Risk of Prostate-specific Antigen Persistence After Radical Prostatectomy? Identifying Indicators of Systemic Disease by Integrating Clinical, Magnetic Resonance Imaging, and Functional Imaging Parameters 108
Preoperative Erectile Function Represents a Significant Predictor of Postoperative Urinary Continence Recovery in Patients Treated With Bilateral Nerve Sparing Radical Prostatectomy 108
Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study☆ 108
Optimizing prostate-targeted biopsy schemes in men with multiple mpMRI visible lesions: should we target all suspicious areas? Results of a two institution series 108
Impact of Early Dorsal Venous Complex Ligation on Urinary Continence Recovery after Robot-assisted Radical Prostatectomy: Results from a Phase 3 Randomized Controlled Trial 107
Does previous prostate surgery affect multiparametric magnetic resonance imaging accuracy in detecting clinically significant prostate cancer? Results from a single institution series 105
Multiparametric magnetic resonance imaging of the prostate underestimates tumour volume of small visible lesions 104
Re: Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-Invasive Bladder Carcinoma with Variant Histologies 102
ASSOCIATION BETWEEN BRCA 1/2 POLYMORPHISMS AND DISEASE AGGRESSIVENESS IN A PROSPECTIVE COHORT OF PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY 101
Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy 100
Defining Clinically Meaningful Positive Surgical Margins in Patients Undergoing Radical Prostatectomy for Localised Prostate Cancer 99
A Head-to-head Comparison of Four Prognostic Models for Prediction of Lymph Node Invasion in African American and Caucasian Individuals 98
ASSOCIATION BETWEEN POLYMORPHISMS OF HOMOLOGOUS RECOMBINATION RAD51B AND DISEASE RECURRENCE IN A PROSPECTIVE COHORT OF PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY 97
Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought 97
DNA methylation alterations in prostate cancer: from diagnosis to treatment 96
A Novel Classification Proposal for Rectourethral Fistulas After Primary Treatment of Prostate Cancer 96
The Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Assessment of Local Recurrence and Distant Metastases in Patients with Biochemical Recurrence of Prostate Cancer After Definitive Treatment: A Systematic Review and Meta-analysis 95
Diagnostic and prognostic factors in patients with prostate cancer: A systematic review protocol 95
Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies 94
Defining the optimal target-to-background ratio to identify positive lymph nodes in prostate cancer patients undergoing robot-assisted [99mTc]Tc-PSMA radioguided surgery: updated results and ad interim analyses of a prospective phase II study 94
Assessing the need for systematic biopsies in addition to targeted biopsies according to the characteristics of the index lesion at mpMRI. Results from a large, multi-institutional database 93
Defining the Most Informative Intermediate Clinical Endpoints for Patients Treated with Salvage Radiotherapy for Prostate-specific Antigen Rise After Radical Prostatectomy 93
Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study 93
Predictive value of preoperative neutrophil-to-lymphocyte ratio in localized prostate cancer: results from a surgical series at a high-volume institution 92
ASSOCIATION BETWEEN RS6152 POLYMORPHISM IN THE ANDROGEN RECEPTOR GENE AND DISEASE AGGRESSIVENESS IN A PROSPECTIVE COHORT OF PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY 91
Association of neurovascular bundle preservation with oncological outcomes in patients with high-risk prostate cancer 91
Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy 91
Assessing the Clinical Value of Positive Multiparametric Magnetic Resonance Imaging in Young Men with a Suspicion of Prostate Cancer 90
There Is No Way to Avoid Systematic Prostate Biopsies in Addition to Multiparametric Magnetic Resonance Imaging Targeted Biopsies 90
Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results from the International Staging Collaboration for Cancer of the Prostate 90
Combined Use of Prostate-specific Antigen Density and Magnetic Resonance Imaging for Prostate Biopsy Decision Planning: A Retrospective Multi-institutional Study Using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD) 90
A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer 90
Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging-targeted Biopsy 89
A nomogram predicting the cancer-specific mortality in patients eligible for radical cystectomy evaluating clinical data and neoadjuvant cisplatinum-based chemotherapy 88
Reducing the Risk of Postoperative Complications After Robot-assisted Radical Prostatectomy in Prostate Cancer Patients: Results of an Audit and Feedback Intervention Following the Implementation of Prospective Data Collection 88
Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer 86
Assessing the Impact of Surgeon Experience on Urinary Continence Recovery after Robot-Assisted Radical Prostatectomy: Results of Four High-Volume Surgeons 86
A SINGLE POSITIVE LYMPH NODE HAS NO DETRIMENTAL EFFECT ON SURVIVAL OF PATIENTS WITH PROSTATE CANCER TREATED WITH EXTENDED PELVIC LYMPH NODE DISSECTION. RESULTS OF A MATCHED CONTROLLED ANALYSIS 85
A NOVEL TOOL FOR THE PREDICTION OF URINARY INCONTINENCE AFTER BILATERAL NERVE SPARING RADICAL PROSTATECTOMY 84
Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series 84
A Systematic Review of Focal Ablative Therapy for Clinically Localised Prostate Cancer in Comparison with Standard Management Options: Limitations of the Available Evidence and Recommendations for Clinical Practice and Further Research 83
External Validation of Nomograms for the Identification of Pelvic Nodal Dissection Candidates Among Prostate Cancer Patients with Negative Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography 82
A detailed analysis of the association between postoperative phosphodiesterase type 5 inhibitor use and the risk of biochemical recurrence after radical prostatectomy 82
A novel tool for the prediction of urinary incontinence after bilateral nerve-sparing radical prostatectomy 82
Introducing PIONEER: a project to harness big data in prostate cancer research 82
A single positive lymph node has no detrimental effect on survival of patients with prostate cancer treated with extended pelvic lymph node dissection. Results of a matched controlled analysis 81
"Trifecta' outcomes of robot-assisted partial nephrectomy in solitary kidney: a Vattikuti Collective Quality Initiative (VCQI) database analysis 79
Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study 79
Reply by Authors 79
Adjuvant chemotherapy is ineffective in patients with bladder cancer and variant histology treated with radical cystectomy with curative intent 78
Prediction of the Need for an Extended Lymphadenectomy at the Time of Radical Cystectomy in Patients with Bladder Cancer 78
Surgical Safety of Radical Cystectomy and Pelvic Lymph Node Dissection Following Neoadjuvant Pembrolizumab in Patients with Bladder Cancer: Prospective Assessment of Perioperative Outcomes from the PURE-01 Trial 78
Prostate-specific Membrane Antigen Imaging in Clinical Guidelines: European Association of Urology, National Comprehensive Cancer Network, and Beyond 78
Author Correction: Introducing PIONEER: a project to harness big data in prostate cancer research (Nature Reviews Urology, (2020), 17, 6, (351-362), 10.1038/s41585-020-0324-x) 77
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent 77
Improving the stratification of intermediate risk prostate cancer 77
Predictors of 30-day acute kidney injury following radical and partial nephrectomy for renal cell carcinoma 76
A SINGLE POSITIVE LYMPH NODE HAS NO DETRIMENTAL EFFECT ON SURVIVAL OF PATIENTS WITH PROSTATE CANCER TREATED WITH EXTENDED PELVIC LYMPH NODE DISSECTION. RESULTS OF A MATCHED CONTROLLED ANALYSIS 76
Association between Lesion Location and Oncologic Outcomes after Focal Therapy for Localized Prostate Cancer Using Either High Intensity Focused Ultrasound or Cryotherapy 76
Distribution of metastatic sites in patients with prostate cancer: A population-based analysis 75
Time for action: actinium-225 PSMA-targeted alpha therapy for metastatic prostate cancer – a systematic review and meta-analysis 74
Safety and Early Oncologic Outcomes of Lung Resection in Patients with Isolated Pulmonary Recurrent Prostate Cancer: A Single-center Experience 74
Technical and Functional Validation of a Teleoperated Multirobots Platform for Minimally Invasive Surgery 73
A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy? 72
Followup of Men with PI-RADS™ 4 or 5 Abnormality on Prostate Magnetic Resonance Imaging and Nonmalignant Pathological Findings on Initial Targeted Prostate Biopsy. Letter 72
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer 71
Risk Stratification of Patients Candidate to Radical Prostatectomy Based on Clinical and Multiparametric Magnetic Resonance Imaging Parameters: Development and External Validation of Novel Risk Groups 70
Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study 69
Conversion of Robot-assisted Partial Nephrectomy to Radical Nephrectomy: A Prospective Multi-institutional Study 67
Short-term perioperative outcomes of patients treated with radical cystectomy for bladder cancer included in the National Surgical Quality Improvement Program (NSQIP) database 67
The Importance of an Adequate Surgical Template During Salvage Lymph Node Dissection for Node-Recurrent Prostate Cancer 67
A Systematic Review of the Impact of Surgeon and Hospital Caseload Volume on Oncological and Nononcological Outcomes After Radical Prostatectomy for Nonmetastatic Prostate Cancer 67
Postoperative phosphodiesterase type 5 inhibitor administration increases the rate of urinary continence recovery after bilateral nerve-sparing radical prostatectomy 65
Racial Disparities in End-of-Life Care Among Patients With Prostate Cancer: A Population-Based Study 65
Tailored use of PSA density according to multiparametric MRI index lesion location: results of a large, multi-institutional series 64
Re: Sophie Knipper, Luigi Ascalone, Benjamin Ziegler, et al. Salvage Surgery in Patients with Local Recurrence After Radical Prostatectomy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.11.012: Surgical Treatment of Local Recurrence Following Radical Prostatectomy: Reality or Illusion? 64
Re-assessment of 30-, 60- and 90-day mortality rates in non-metastatic prostate cancer patients treated either with radical prostatectomy or radiation therapy 64
Metastatic hormone‑sensitive prostate cancer: local treatment strategies 63
The added value of artificial intelligence using Quantib Prostate for the detection of prostate cancer at multiparametric magnetic resonance imaging 62
A systematic review of the association between erectile dysfunction and cardiovascular disease 62
Totale 11.064
Salva come PNG Salva come JPEG
Categoria #
all - tutte 167.236
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 167.236
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20216 0 0 0 0 0 0 0 0 0 6 0 0
2021/2022364 0 48 39 116 13 19 31 24 10 14 21 29
2022/20232.140 964 443 116 26 15 230 91 136 59 8 28 24
2023/20241.237 24 48 106 92 89 214 116 126 16 110 122 174
2024/20256.038 829 157 149 140 174 496 722 500 1.105 887 407 472
2025/202616.218 1.213 1.445 1.359 2.567 1.190 399 1.476 1.188 4.589 792 0 0
Totale 26.283